Short-Term Outcome of Infliximab Therapy in Pediatric Crohn's Disease: A Single-Center Experience.
10.5223/pghn.2017.20.4.236
- Author:
Dai JUNG
1
;
Sunghee LEE
;
Insook JEONG
;
Seak Hee OH
;
Kyung Mo KIM
Author Information
1. Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea. seakhee.oh@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Crohn disease;
Child;
Infliximab
- MeSH:
Child;
Cohort Studies;
Crohn Disease*;
Diagnosis;
Hematocrit;
Humans;
Infliximab*;
Korea;
Multivariate Analysis;
Prognosis;
Retrospective Studies
- From:Pediatric Gastroenterology, Hepatology & Nutrition
2017;20(4):236-243
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Studies on the efficacy of infliximab (IFX) in a large population of pediatric patients with Crohn's disease (CD) are limited, and prognostic factors are not well-known. The aim of this study was to evaluate outcomes of IFX in pediatric patients with CD and to identify factors associated with poor prognosis. METHODS: We retrospectively analyzed medical data of 594 pediatric patients with CD between 1987 and 2013 in a tertiary center. Of these, 156 children treated with IFX were enrolled and were followed up for at least a year with intact data. Outcomes of induction and maintenance, classified as failure or clinical response, were evaluated on the tenth and 54th week of IFX therapy. RESULTS: We treated 156 pediatric patients with CD with IFX, and the median duration of IFX therapy was 47 months. For IFX induction therapy, 134 (85.9%) patients experienced clinical response on the 10th week. Among the 134 patients who showed response to induction, 111 (82.8%) patients maintained the clinical response on the 54th week. In multivariate analysis, low hematocrit (p=0.046) at the time of IFX initiation was associated with the failure of IFX induction. For IFX maintenance therapy, longer duration from the initial diagnosis to IFX therapy (p=0.017) was associated with maintenance failure on the 54th week. CONCLUSION: We have shown the acceptable outcomes of IFX in a large cohort of pediatric CD patients in Korea. Hematocrit and early introduction of IFX may be prognostic factors for the outcomes of IFX.
